agents and antineoplastic agents

Mittmann, Ulrich; Sachetto, Jean-Pierre

PATENT ASSIGNEE(S): Tillotts Pharma AG, Switz. SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

INVENTOR(S):

Patent English

LANGUAGE: FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.				KIND DATE			APPLICATION NO.						DATE				
WO 2005123061				A1 20051229			1	WO 2005-EP6413				20050615					
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES;	FΙ,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KM,	ΚP,	KR,	ΚZ,
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,
		NG,	NI,	NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,
		SL,	SM,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,
		ZA,	ZM,	ZW													
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
		ΑZ,	BY,	KG,	·ΚΖ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	IS,	IT,	LT,	LU,	MC,	NL,	PL,	PT,
		RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,
		MR,	NE,	SN,	TD,	ΤG											

PRIORITY APPLN. INFO.:

GB 2004-13730 A 20040618

ED Entered STN: 30 Dec 2005

Polyunsatd. fatty acid ("PUFA") or a pharmacol. acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent or a pharmacol. acceptable salt or derivative thereof in the treatment of conditions involving acutely or chronically inadequate immune response by topical application of said active agents to at least a portion of the intestinal mucosa. Specific conditions that may be treated include chronic inflammatory disease (e.g. Chrohn's disease and ulcerative colitis) and tumor disease (e.g. bowel cancer and prostate cancer). One advantage of preferred embodiments of the invention is that bioavailability of immunosuppressive or antineoplastic agents is increased. For example, capsules contained fish oil (over 60% of DHA and Incromega 3F60 EPA), Eudragit NE 30D coating, polysorbate 80.

REFERENCE COUNT:

10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L139 ANSWER 60 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN 2005:1355507 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER:

144:74884

TITLE:

A pharmaceutical compositions containing

polyunsaturated fatty acids in combination with immunosuppressive agents and antineoplastic agents

INVENTOR(S): Mittmann, Ulrich; Sachetto, Jean-Pierre

PATENT ASSIGNEE(S):

Tillotts Pharma AG, Switz.

SOURCE:

PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123060	A1	20051229	WO 2005-EP6412	20050615



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 2004-13729

A 20040618

Entered STN: 30 Dec 2005

Polyunsatd. fatty acid ("PUFA") or a pharmacol. acceptable salt or derivative AΒ thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent or a pharmacol. acceptable salt or derivative thereof in the treatment of conditions involving acutely or chronically inadequate immune response by topical application of said active agents to at least a portion of the intestinal mucosa. Specific conditions that may be treated include chronic inflammatory disease (e.g. Chrohn's disease and ulcerative colitis) and tumor disease (e.g. bowel cancer and prostate cancer). One advantage of preferred embodiments of the invention is that bioavailability of immunosuppressive or antineoplastic agents is increased. For example, capsules contained fish oil (over 60% of DHA and Incromega 3F60 EPA), Eudragit NE 30D coating, polysorbate 80.

REFERENCE COUNT:

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L139 ANSWER 61 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN ACCESSION NUMBER: 2005:1223775 HCAPLUS Full-text

DOCUMENT NUMBER:

143:483122

TITLE:

Methods and articles for the delivery of drugs to the

eye for the treatment of posterior segment diseases

INVENTOR(S):

Schultz, Clyde

PATENT ASSIGNEE(S):

Directcontact LLC, USA

SOURCE:

U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S.

Ser. No. 971,997.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	<del>-</del>			-	
US 2005255144	A1	20051117	US 2005-102454		20050409
US 2005208102	A1	20050922	US 2004-821718		20040409
US 2005074497	A1	20050407	US. 2004-971997		20041022
PRIORITY APPLN. INFO.:			US 2003-461354P	P	20030409
			US 2004-821718	A2	20040409
			US 2004-971997	Α2	20041022

ED Entered STN: 18 Nov 2005

This invention provides articles and methods for drug delivery including a AB hydrogel containing one or more drugs for the treatment of a posterior segment disease and/or dry eye conditions. Exemplary drugs are anti-angiogenesis compds. for the treatment of macular degeneration. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended



period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concns. of compds., e.g., from eye drops.

L139 ANSWER 62 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2005:983601 HCAPLUS Full-text

DOCUMENT NUMBER:

143:272523

TITLE:

Stable ophthalmic oil-in-water emulsions containing

sodium hyaluronate for alleviating dry eye

INVENTOR(S):

Yu, Zhi-Jian; Huth, Stanley W.; Crawford, Lauren L.;

Cook, James N.

PATENT ASSIGNEE(S):

USA

SOURCE:

U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S.

Ser. No. 802,153.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005196370	A1	20050908	US 2005-98827	20050404
US 2004185068	A1	20040923	US 2003-392375	20030318
US 2004191284	A1	20040930	US 2004-802153	20040317
PRIORITY APPLN. INFO.:			US 2003-392375	A2 20030318
			US 2004-802153	A2 20040317

ED Entered STN: 09 Sep 2005

AB Stable oil-in-water emulsions are described which contain a demulcent for the treatment of dry eye such as sodium hyaluronate. The oil-in-water emulsions are stable and have anti-microbial activity sufficient for use as contact lens disinfecting solns. Thus, an emulsion contained sodium chlorite 65 and WSCP 3 ppm, sodium hyaluronate 0.1, castor oil 1.25, ethoxylated hydrogenated castor oil 1, boric acid 0.6, sodium borate decahydrate 0.035, calcium chloride dihydrate 0.006, MgCl2.6H2O 0.006, KCl 0.14, NaCl 3.5, and water qs to 100%.

L139 ANSWER 63 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2004:902155 HCAPLUS Full-text

DOCUMENT NUMBER:

141:384286

TITLE:

Novel encochleation methods, cochleates and methods of

use

INVENTOR(S):

Mannino, Raphael J.; Gould-Fogerite, Susan;

Krause-Elsmore, Sara L.; Delmarre, David; Lu, Ruying

PATENT ASSIGNEE(S):

Biodelivery Sciences International, Inc., USA;

University of Medicine and Dentistry of New Jersey

SOURCE: PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091578	A2	20041028	WO 2004-US11026	20040409
WO 2004091578	C1	20050127	•	
WO 2004091578	A3	20050331		



```
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
    US 2005013854
                                20050120
                                            US 2004-822230
                                                                    20040409
                          Α1
    EP 1624858
                          A2
                                20060215
                                            EP 2004-759375
                                                                   20040409
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
PRIORITY APPLN. INFO.:
                                            US 2003-461483P
                                                                   20030409
                                            US 2003-463076P
                                                                Ρ
                                                                   20030415
                                            US 2003-499247P
                                                                Р
                                                                   20030828
                                            US 2003-502557P
                                                                P 20030911
                                            US 2003-532755P
                                                                P 20031224
                                            US 2004-537252P
                                                                P 20040115
                                                                Ρ
                                            US 2004-556192P
                                                                   20040324
                                            WO 2004-US11026
                                                                W 20040409
```

ED Entered STN: 28 Oct 2004

AB The invention generally relates to cochleate drug delivery vehicles. Disclose are novel methods for making cochleates and cochleate compns. that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compns. that include an aggregation inhibitor, and optionally, a cargo moiety. Addnl., anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a neg. charge lipid are disclosed. Methods of using the cochleate compns. of the invention, including methods of administration, are also disclosed.

```
L139 ANSWER 64 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:
                        2004:100508 HCAPLUS Full-text
DOCUMENT NUMBER:
                        140:157440
```

TITLE: Methods for treating an autoimmune disease using a

soluble CTLA4 molecule in combination with a DMARD or

INVENTOR(S): Cohen, Robert; Carr, Suzette; Hagerty, David; Peach,

Robert J.; Becker, Jean-Claude

PATENT ASSIGNEE(S):

U.S. Pat. Appl. Publ., 189 pp., Cont.-in-part of U.S. SOURCE:

Ser. No. 898,195.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004022787	A1	20040205	US 2003-419008	20030418
US 2003083246	A1	20030501	US 2001-898195	20010702
PRIORITY APPLN. INFO.:			US 2000-215913P P	20000703
			US 2001-898195 A	2 20010702

Entered STN: 08 Feb 2004 ED

AB The present invention relates to compns. and methods for treating immune system diseases such as rheumatic disease, by administering to a subject



soluble CTLA4 (cytotoxic T lymphocyte antigen 4) mols. that block endogenous B7 (CD80) mols. from binding their ligands, alone, or in conjunction with other agents including disease modifying anti-rheumatic drugs (DMARDs) or nonsteroidal anti-inflammatory drugs (NSAIDs). The soluble CTLA4 mol. comprises the extracellular domain (residues 1-124) of full-length human CTLA4, which may be fused at the N-terminus with the signal peptide of oncostatin M and at the C-terminal end with an Igyl constant region. Single-site and double-site CTLA4 mutant sequences are also constructed, including L104E/A29Y-CTLA4/Ig, L104E/A29L-CTLA4/Ig, L104E/A29T-CTLA4/Ig, and L104E/A29W-CTLA4/Ig. CTLA4/Ig administered at 10 mg/kg (plus methotrexate) has superior efficacy in treatment of rheumatoid arthritis compared to placebo (plus methotrexate) based on efficacy parameters of the American Collage of Rheumatol. Core Data Set and Response Definitions (ACR). Binding kinetics to CD86 and CD80, pharmacokinetics, and pharmacodynamics of C-reactive protein, rheumatoid factor, interleukin-2 receptor, interleukin -6, and tumor necrosis factor  $\alpha$ are provided.

L139 ANSWER 65 OF 73 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2002:9767 HCAPLUS Full-text

DOCUMENT NUMBER:

136:74627

TITLE:

Drug compositions containing cyclosporin and

their application as topical systems

INVENTOR(S):

Wohlrab, Johannes; Neubert, Reinhard; Jahn, Konstanze

PATENT ASSIGNEE(S): Germany

SOURCE:

Ger. Offen., 14 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

LANGUAGE:

Patent German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.			KIND DATE			APPLICATION NO.						DATE					
DE								DE 2000-10029404					20000615				
CA	CA 2470230				AA 20030626			CA 2001-2470230					20011214				
WO	2003	0513	85					WO 2001-EP14749									
	W:																
											EE,						
											KG,						
											MW,						-
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	TZ,
		UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW					·	·	•
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
											CY,						
											BF,						
							NE,				•	·		·	•	·	•
ΑU	2002	2317	03		A1		2003	0630		AU 2	002-	2317	03		2	0011	214
ΕP	1455	810			A1		2004	0915		EP 2	001-	9918	45		2	0011	214
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
							RO,										
BR	2001	0171	97		Α		2004	1214		BR 2	001-	1719	7		2	0011	214
CN	1582	161			Α		2005	0216		CN 2	001-	8239	50		2	0011	214
US	2005	1061	89		A1		2005	0519		US 2	003-	4986	56		2	0011	214
JP	2005	5169	31		Т2		2005	0609		JP 2	003-	5523	18		2	0011	214
NΖ	5340	61			Α		2006	0127		NZ 2	001-	5340	61		2	0011	214
NO	2004	0030	01		Α		2004	0914		NO 2	004-	3001			2	0040	713
RITY	APP	LN.	INFO	.:						DE 2	000-	1002	9404		A 2	0000	615
									1	WO 2	001-	EP14	749		W 2	0011	214
F.nt	ered	STN	. 04	4 .Tai	200	12											

PRIO

# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

